TY - JOUR
T1 - Measuring and targeting aldosterone and renin in atherosclerosis-A review of clinical data
AU - Hillaert, Marieke A.
AU - Lentjes, Eef G.
AU - Beygui, Farzin
AU - Kemperman, Hans
AU - Asselbergs, Folkert W.
AU - Nathoe, Hendrik M.
AU - Agostoni, Pierfrancesco
AU - Voskuil, Michiel
AU - Ivanes, Fabrice
AU - Jude, Brigitte
AU - Bertrand, Michel E.
AU - Pasterkamp, Gerard
AU - van der Graaf, Yolanda
AU - Doevendans, Pieter A.
AU - Montalescot, Gilles
AU - van Belle, Eric
PY - 2011/10
Y1 - 2011/10
N2 - Our understanding of the development and progression of atherosclerosis has increased substantially over the past decades. A significant role for the renin-angiotensin-aldosterone system (RAAS) in this process has gained appreciation in recent years. Preclinical and clinical studies have associated components of the RAAS with various cardiovascular disease conditions. Classically known for its contribution to hypertension, dysregulation of the system is now also believed to promote vascular inflammation, fibrosis, remodeling, and endothelial dysfunction, all intimately related to atherosclerosis. The reduction in cardiovascular mortality and morbidity, as seen with the use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, supports the concept that RAAS is involved in the pathogenesis of atherosclerotic disease. However, the underlying molecular mechanisms of the pathophysiology remain to be completely understood. Evidence points toward additional benefit from therapeutic approaches aiming at more complete inhibition of the system and the possible utility of renin or aldosterone in the prediction of cardiovascular outcome. This review will summarize the current knowledge from clinical studies regarding the presumptive role of renin and aldosterone in the prediction and management of patients with atherosclerosis. For this purpose, a literature search was performed, focusing on available clinical data regarding renin or aldosterone and cardiovascular outcome. © 2011 Mosby, Inc. All rights reserved.
AB - Our understanding of the development and progression of atherosclerosis has increased substantially over the past decades. A significant role for the renin-angiotensin-aldosterone system (RAAS) in this process has gained appreciation in recent years. Preclinical and clinical studies have associated components of the RAAS with various cardiovascular disease conditions. Classically known for its contribution to hypertension, dysregulation of the system is now also believed to promote vascular inflammation, fibrosis, remodeling, and endothelial dysfunction, all intimately related to atherosclerosis. The reduction in cardiovascular mortality and morbidity, as seen with the use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, supports the concept that RAAS is involved in the pathogenesis of atherosclerotic disease. However, the underlying molecular mechanisms of the pathophysiology remain to be completely understood. Evidence points toward additional benefit from therapeutic approaches aiming at more complete inhibition of the system and the possible utility of renin or aldosterone in the prediction of cardiovascular outcome. This review will summarize the current knowledge from clinical studies regarding the presumptive role of renin and aldosterone in the prediction and management of patients with atherosclerosis. For this purpose, a literature search was performed, focusing on available clinical data regarding renin or aldosterone and cardiovascular outcome. © 2011 Mosby, Inc. All rights reserved.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=80053641993&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/21982648
U2 - https://doi.org/10.1016/j.ahj.2011.06.015
DO - https://doi.org/10.1016/j.ahj.2011.06.015
M3 - Review article
C2 - 21982648
SN - 0002-8703
VL - 162
SP - 585
EP - 596
JO - American Heart Journal
JF - American Heart Journal
IS - 4
ER -